ad

Godavari Drugs Q2 Results FY27: Profit Moves Against Revenue, Revenue Rs 28.23 Cr, PAT Rs 0.96 Cr

11 Nov 2026 • 6:12 pm

Godavari Drugs Q2 Results FY27: Profit Moves Against Revenue, Revenue Rs 28.23 Cr, PAT Rs 0.96 Cr

Quick Answer

Godavari Drugs Q2 Results FY27 were declared on 11 November 2026. These quarterly results on a Standalone basis show revenue of Rs 28.23 Cr, up 5.93% from Rs 26.65 Cr a year earlier, and net profit of Rs 0.96 Cr, down 4% from Rs 1 Cr. Operating Profit stood at Rs 2.8 Cr, up 40% YoY. The YoY growth picture is detailed in the Financial Highlights table and the sections that follow.

Godavari Drugs Ltd (GODAVARI) Q2 Results FY27 announced on 11 November 2026, covering the company's financial performance for the July to September quarter. The Godavari Drugs Q2 Results FY27 record revenue of Rs 28.23 Cr and net profit of Rs 0.96 Cr on a Standalone basis. The results date of 11 November 2026 marks the point from which this standalone results filing for Godavari Drugs is available to investors tracking NSE and BSE disclosures, and the sections below read the numbers in order.

This results analysis of Godavari Drugs Q2 Results covers the financial highlights, the business drivers disclosed for the quarter, the FY27 outlook and the risks worth tracking. Revenue moved higher while net profit moved lower on a YoY basis, and the Financial Highlights comparison below sets each line against the same quarter a year earlier so the YoY movement can be read at a glance.

Click Here – Get Free Investment Predictions

Godavari Drugs Q2 Results FY27: Financial Highlights

Metric Q2 FY27 (Sep 26) Q2 FY26 (Sep 25) YoY Change
Revenue Rs 28.23 Cr Rs 26.65 Cr +5.93% YoY
Operating Profit Rs 2.8 Cr Rs 2 Cr +40% YoY
Net Profit (PAT) Rs 0.96 Cr Rs 1 Cr -4% YoY

Source: company filing for Godavari Drugs Q2 Results FY27, 11 November 2026. Figures in Rs Crore, Standalone basis.

Key Takeaways from Godavari Drugs Q2 Results: What Stands Out

  • Revenue of Rs 28.23 Cr was up 5.93% YoY, compared with Rs 26.65 Cr in the same quarter of the previous year, according to the Godavari Drugs Q2 Results FY27 data.
  • Net profit of Rs 0.96 Cr was down 4% YoY from Rs 1 Cr, so the YoY growth in net profit moved separately from revenue.
  • Operating Profit of Rs 2.8 Cr was up 40% YoY against Rs 2 Cr, which is the middle profit line between revenue and PAT.
  • Standalone results are what the figures above are based on, and the results were declared on 11 November 2026.
  • The next section moves from these headline figures to the detailed performance analysis of the quarter.

Godavari Drugs Q2 Results FY27: Performance Analysis

Godavari Drugs reported revenue of Rs 28.23 Cr for the July to September quarter, up 5.93% YoY from Rs 26.65 Cr, while net profit came in at Rs 0.96 Cr, down 4% from Rs 1 Cr. Revenue moved higher while net profit moved lower on a YoY basis, and Operating Profit also moved up 40% YoY to Rs 2.8 Cr.

Across the Godavari Drugs Q2 Results FY27 figures, the revenue line and the profit lines tell different parts of the story. Revenue rose by 5.93% YoY, Operating Profit rose by 40% YoY and net profit fell by 4% YoY. The supplied data confirms these movements but does not establish the specific cause of each one, so the disclosed drivers are covered in the next section.

In this results analysis of Godavari Drugs Q2 Results, investors usually compare the same quarter across years to separate seasonal patterns from changes in the business. The YoY growth rates above follow that approach, and later quarterly results filed by Godavari Drugs will show whether these levels hold. For now, the results analysis turns to the business factors.

Check the Univest Screener for live results data

Key Business Factors This Quarter

Revenue Growth YoY – The results analysis points to this disclosed driver first: Revenue grew 5.9% year on year to Rs 28.23 Cr in the latest quarter. This sets the revenue base of Rs 28.23 Cr for the Godavari Drugs Q2 Results FY27 reading and anchors the YoY comparison with Rs 26.65 Cr a year earlier.

Revenue Growth Quarter on Quarter – Revenue was up 1.0% quarter on quarter from Rs 27.96 Cr. It places the latest quarter in sequence with the previous one, and it supports the reading of the quarterly results beyond the YoY comparison alone.

Operating Profit Movement – Operating Profit was Rs 2.8 Cr against Rs 2 Cr a year earlier, a YoY change of 40% higher. This line sits between revenue and net profit of Rs 0.96 Cr, so it links the top line to the final profit figure in this standalone results filing.

FY27 Outlook After Godavari Drugs Q2 Results

The Godavari Drugs Q2 Results FY27 cover only one quarter of FY27, so the full-year picture depends on the quarters still to be reported. With net profit at Rs 0.96 Cr and revenue at Rs 28.23 Cr in this quarter, the next results analysis will show how the YoY growth trend builds across the year.

This section avoids any projection and relies only on the declared figures. Investors can track Godavari Drugs on the Univest Screener and in the Univest app to see how net profit and revenue develop as each quarterly result is declared, and the next section covers the risks to watch.

Key Risks to Watch After Godavari Drugs Q2 Results FY27

Net Profit Fell YoY

Net profit fell 4.0% year on year to Rs 0.96 Cr. This is a point to read alongside the Godavari Drugs Q2 Results FY27 figures and the standalone results basis.

Low Return on Equity

Return on equity was low at 7.18% in FY26.

Modest Return on Capital Employed

Return on capital employed was modest at 6.81% in FY26. Tracking this against YoY growth in later quarters will show whether the picture changes.

Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.

Conclusion

Godavari Drugs Q2 Results FY27 show Godavari Drugs reporting revenue of Rs 28.23 Cr and net profit of Rs 0.96 Cr in July to September 2026 on a Standalone basis. Investors reading the quarterly results and Godavari Drugs Q2 Results data alongside the standalone results may want to consult a SEBI-registered advisor before acting on any of these numbers.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.

Frequently Asked Questions on Godavari Drugs Q2 Results FY27

What are Godavari Drugs Q2 Results FY27?

Ans. Godavari Drugs Q2 Results FY27 cover the July to September 2026 quarter of Godavari Drugs, showing standalone revenue of Rs 28.23 Cr and net profit of Rs 0.96 Cr. The Quick Answer at the top summarises them.

What is the results date for Godavari Drugs Q2 Results FY27?

Ans. Godavari Drugs declared its Q2 FY27 results on 11 November 2026, so that is the results date for the July to September 2026 quarter. Alongside this, the intro of this article covers the filing context.

What revenue was reported in Godavari Drugs Q2 Results FY27?

Ans. Godavari Drugs reported revenue of Rs 28.23 Cr in Godavari Drugs Q2 Results FY27, compared with Rs 26.65 Cr a year earlier, while the Financial Highlights table sets both quarters side by side.

What net profit was reported in Godavari Drugs Q2 Results FY27?

Ans. Godavari Drugs reported net profit of Rs 0.96 Cr, against Rs 1 Cr in the same quarter last year, while the Key Takeaways section places this net profit beside revenue and Operating Profit.

How much YoY growth did revenue show in Godavari Drugs Q2 Results FY27?

Ans. Revenue rose 5.93% YoY to Rs 28.23 Cr from Rs 26.65 Cr in the standalone results of Godavari Drugs, which means the YoY growth figure compares the same quarter, as covered in Performance Analysis.

Did net profit rise or fall in Godavari Drugs Q2 Results?

Ans. Net profit fell 4% YoY in Godavari Drugs Q2 Results, moving to Rs 0.96 Cr from Rs 1 Cr, while the Performance Analysis section sets this against the revenue and Operating Profit movement.

What was the Operating Profit in Godavari Drugs Q2 Results FY27?

Ans. Operating Profit was Rs 2.8 Cr in Godavari Drugs Q2 Results FY27, up 40% YoY from Rs 2 Cr, which means it is the middle profit line between revenue and net profit, as discussed in Performance Analysis.

Are Godavari Drugs Q2 Results consolidated results or standalone results?

Ans. Godavari Drugs Q2 Results are standalone results for Godavari Drugs, so every revenue, Operating Profit and net profit figure refers to the standalone basis, as stated in the Quick Answer and again in the Conclusion section.

What business factors shaped Godavari Drugs Q2 Results FY27?

Ans. The disclosed factors for Godavari Drugs Q2 Results FY27 are a 5.93% YoY revenue change and revenue up 1.0% quarter on quarter from Rs 27.96 Cr, so the Key Business Factors section links each one to the quarter.

What are the key risks after Godavari Drugs Q2 Results FY27?

Ans. Godavari Drugs lists a YoY fall in net profit, low return on equity and modest return on capital employed as points to watch, so the Key Risks section explains each alongside the Godavari Drugs Q2 Results FY27 figures.

What is the outlook after Godavari Drugs Q2 Results?

Ans. Godavari Drugs Q2 Results cover only the July to September quarter of FY27, so the FY27 outlook depends on later quarterly results. Alongside this, the Outlook section avoids projections and relies only on the declared figures.

Where can I find the complete Godavari Drugs Q2 Results FY27 data?

Ans. The complete Godavari Drugs Q2 Results FY27 data sits in the Financial Highlights table, which sets revenue, Operating Profit and net profit against the same quarter a year earlier. The Univest Screener also lists the latest Godavari Drugs figures.


Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down